Biohaven Pharmaceutical Holding Co Ltd (BHVN) Reaches $38.00 High on Sep, 2; Schafer Cullen Capital Management Has Cut Nippon Telegraph & Telephone C (NTT) Holding By $18.61 Million

September 2, 2017 - By Ellis Scott

The stock of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) reached all time high today, Sep, 2 and still has $39.90 target or 5.00% above today’s $38.00 share price. This indicates more upside for the $1.37 billion company. This technical setup was reported by Barchart.com. If the $39.90 PT is reached, the company will be worth $68.50 million more. The stock increased 6.29% or $2.25 on September 1, reaching $38. About shares traded. Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has 0.00% since September 2, 2016 and is . It has underperformed by 16.70% the S&P500.

Schafer Cullen Capital Management Inc decreased Nippon Telegraph & Telephone C (NTT) stake by 24.05% reported in 2016Q4 SEC filing. Schafer Cullen Capital Management Inc sold 442,981 shares as Nippon Telegraph & Telephone C (NTT)’s stock 0.00%. The Schafer Cullen Capital Management Inc holds 1.40 million shares with $58.84 million value, down from 1.84 million last quarter. Nippon Telegraph & Telephone C now has $101.37 billion valuation. The stock decreased 2.53% or $1.26 during the last trading session, reaching $48.48. About 20,795 shares traded. Nippon Telegraph & Telephone Corp (ADR) (NYSE:NTT) has 0.00% since September 2, 2016 and is . It has underperformed by 16.70% the S&P500.

Schafer Cullen Capital Management Inc increased Opap Sa (Adr) (GOFPY) stake by 75,425 shares to 555,415 valued at $2.46M in 2016Q4. It also upped Vina Concha Y Toro Sa (Adr) (NYSE:VCO) stake by 61,354 shares and now owns 128,784 shares. Cnooc Ltd (CEOHF) was raised too.

Analysts await Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) to report earnings on September, 15. After $-1.74 actual earnings per share reported by Biohaven Pharmaceutical Holding Co Ltd for the previous quarter, Wall Street now forecasts -67.24% EPS growth.

Biohaven Pharmaceutical Holding Company Ltd. is a United States biopharmaceutical company. The company has market cap of $1.37 billion. The Firm is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It currently has negative earnings. It has a portfolio of multiple late-stage drug candidates.